SYK Quote, Financials, Valuation and Earnings

Becton Dickinson & has a net margin of 8.48% compared to Stryker's net margin of 5.86%. Stryker's return on equity of 15.22% beat Becton Dickinson &'s return on equity of 6.75%.

Stryker has a consensus price target of $423.76, signalling upside risk potential of 15.41%. On the other hand Becton Dickinson & has an analysts' consensus of $276.37 which suggests that it could grow by 21.21%. Given that Becton Dickinson & has higher upside potential than Stryker, analysts believe Becton Dickinson & is more attractive than Stryker.

Stryker has a beta of 0.946, which suggesting that the stock is 5.393% less volatile than S&P 500. In comparison Becton Dickinson & has a beta of 0.355, suggesting its less volatile than the S&P 500 by 64.526%.

Stryker has a quarterly dividend of $0.84 per share corresponding to a yield of 0.88%. Becton Dickinson & offers a yield of 1.75% to investors and pays a quarterly dividend of $1.04 per share. Stryker pays 40.73% of its earnings as a dividend. Becton Dickinson & pays out 64.52% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Stryker quarterly revenues are $6.4B, which are larger than Becton Dickinson & quarterly revenues of $5.2B. Stryker's net income of $546M is higher than Becton Dickinson &'s net income of $303M. Notably, Stryker's price-to-earnings ratio is 47.39x while Becton Dickinson &'s PE ratio is 37.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stryker is 6.28x versus 3.21x for Becton Dickinson &. Usually stocks with elevated PS ratios are considered overvalued.

Boston Scientific has a net margin of 8.48% compared to Stryker's net margin of 12.41%. Stryker's return on equity of 15.22% beat Boston Scientific's return on equity of 8.96%.

Stryker has a consensus price target of $423.76, signalling upside risk potential of 15.41%. On the other hand Boston Scientific has an analysts' consensus of $115.62 which suggests that it could grow by 12.98%. Given that Stryker has higher upside potential than Boston Scientific, analysts believe Stryker is more attractive than Boston Scientific.

Stryker has a beta of 0.946, which suggesting that the stock is 5.393% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.772, suggesting its less volatile than the S&P 500 by 22.845%.

Stryker has a quarterly dividend of $0.84 per share corresponding to a yield of 0.88%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stryker pays 40.73% of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend. Stryker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Stryker quarterly revenues are $6.4B, which are larger than Boston Scientific quarterly revenues of $4.6B. Stryker's net income of $546M is lower than Boston Scientific's net income of $566M. Notably, Stryker's price-to-earnings ratio is 47.39x while Boston Scientific's PE ratio is 81.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stryker is 6.28x versus 9.08x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical has a net margin of 8.48% compared to Stryker's net margin of 28.41%. Stryker's return on equity of 15.22% beat Intuitive Surgical's return on equity of 15.6%.

Stryker has a consensus price target of $423.76, signalling upside risk potential of 15.41%. On the other hand Intuitive Surgical has an analysts' consensus of $626.53 which suggests that it could grow by 23.08%. Given that Intuitive Surgical has higher upside potential than Stryker, analysts believe Intuitive Surgical is more attractive than Stryker.

Stryker has a beta of 0.946, which suggesting that the stock is 5.393% less volatile than S&P 500. In comparison Intuitive Surgical has a beta of 1.426, suggesting its more volatile than the S&P 500 by 42.616%.

Stryker has a quarterly dividend of $0.84 per share corresponding to a yield of 0.88%. Intuitive Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stryker pays 40.73% of its earnings as a dividend. Intuitive Surgical pays out -- of its earnings as a dividend. Stryker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Stryker quarterly revenues are $6.4B, which are larger than Intuitive Surgical quarterly revenues of $2.4B. Stryker's net income of $546M is lower than Intuitive Surgical's net income of $685.7M. Notably, Stryker's price-to-earnings ratio is 47.39x while Intuitive Surgical's PE ratio is 79.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stryker is 6.28x versus 22.06x for Intuitive Surgical. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of 8.48% compared to Stryker's net margin of 16.85%. Stryker's return on equity of 15.22% beat Insulet's return on equity of 43.11%.

Stryker has a consensus price target of $423.76, signalling upside risk potential of 15.41%. On the other hand Insulet has an analysts' consensus of $314.06 which suggests that it could grow by 18.57%. Given that Insulet has higher upside potential than Stryker, analysts believe Insulet is more attractive than Stryker.

Stryker has a beta of 0.946, which suggesting that the stock is 5.393% less volatile than S&P 500. In comparison Insulet has a beta of 1.285, suggesting its more volatile than the S&P 500 by 28.544%.

Stryker has a quarterly dividend of $0.84 per share corresponding to a yield of 0.88%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stryker pays 40.73% of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend. Stryker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Stryker quarterly revenues are $6.4B, which are larger than Insulet quarterly revenues of $597.5M. Stryker's net income of $546M is higher than Insulet's net income of $100.7M. Notably, Stryker's price-to-earnings ratio is 47.39x while Insulet's PE ratio is 45.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stryker is 6.28x versus 9.45x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.